Tag Archives: cancer

International Symposium on the Accessibility to High-Value Medicine, December 5-6, 2017 in London

LONDON, Dec-3-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies.

The not-for-profit executive forum is organised by the London School of Hygiene and Tropical Medicine and analytica|LASER, a global research consultancy, to investigate topical questions around drug policy, global health systems sustainability and innovation funding through a combination of case studies, panel sessions, and roundtables. Delegations are registered from over 70 public and private organisations, including the World Health Organization, as well as health systems representatives from Belgium, England, Estonia, Croatia, France, Germany, Italy, Norway, Sweden, the United States and Wales. Multiple patient organisations support the meeting to ensure that the patient voice is reflected in all deliberations.

“Access to life-saving drugs is not a new challenge. The paradigm of accessibility was changed completely in the face of the deadly HIV epidemic. This time, however, accessibility concerns almost every domain of medicine such as cancer, auto-immune diseases and rare diseases. We must act now,” says Prof Peter Piot, Director of the London School of Hygiene & Tropical Medicine and former head of UNAIDS.

“There is an incredible challenge for the sustainability of health systems across the world”, says Prof. Lucien Abenhaim, London School of Hygiene & Tropical Medicine and Chairman of Analytica Laser. “It is critical that drug developers and health system engage on actionable proposals that address concerns around value, cost and overall access to innovation for the patients who need it. We are at an inflection point – the paradigms of the 1990’s can no longer guide us,” he adds.

Yann Le Cam, CEO of EURORDIS-Rare Diseases Europe, an alliance of over 700 rare disease patient organisations, commented, “The majority of people living with a rare disease have delayed or no access to the medicine they need. Only through a collective engagement between all stakeholders involved, including industry, competent authorities, health ministries, academics and regulators, can we break the access deadlock.” Le Cam will be presenting a new four-pillar approach to improve access to rare disease therapies in Europe.

The main plenary on December 6th features scheduled remarks by over a dozen authorities in the field, including Professor Baron Peter Piot (Director, London School of Hygiene & Tropical Medicine and former Head, UNAIDS), Dr. Olivier Brandicourt (Chief Executive Officer, Sanofi), Dr. Sarah Garner (World Health Organization), Prof. Dominique Le Guludec (President, French HAS), Sir Andrew Dillon (Chief Executive, National Institute for Health and Care Excellence UK) and Dr. Harold Paz (Chief Medical Officer, Aetna). The plenary is preceded by a scientific seminar on December 5th which gathers globally renowned academics to explore new frontiers on the methodology for the appraisal and valuation of high-value medicines.

Please contact the organisers for more information on the programming and media access, or refer to www.accessibility-symposium.org

SOURCE: EuropaWire

GenQual Announces Initial Closing Of Its First Preferred Equity Funding Round

GenQual is pleased to announce initial closing of its first preferred equity round. Financial terms were not disclosed. This inaugural funding round allows GenQual to pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb and other JAK/STAT inhibitors for autoimmune diseases and oncology indications. GenQual aims to prospectively identify responders for clinical-stage therapeutics to improve drug trial response rates and improve chances for drug approval. The round remains open for further funding.

GenQual Founder and CEO Jonathan Mirich said, “This funding round allows GenQual to pursue its business development goals to deliver companion diagnostics for very expensive IL-6 monoclonal antibody treatment for autoimmune disease, chiefly rheumatoid arthritis, as well as certain oncology indications. It allows us to extend collaborative agreements for proof-of-principle testing. We are very excited about the possibilities in this space.”

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications. Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level. GenQual is a privately-held corporation based in the Seattle area.

Via EPR Network
More Biotech press releases

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome, The NIDO Disease

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Via EPR Network
More Biotech press releases

New Transplant Therapy, Shift in Drug Discovery

On August 23-25, 2010, industry scientists, CEOs, and academics will convene at Philadelphia’s Four Seasons Hotel for the “Ubiquitin Drug Discovery and Diagnostics Conference” to discuss the Next Big Thing in drug discovery research—the ubiquitin pathway. Advances in oncology, infectious diseases, neurodegeneration, inflammation, diabetes, and muscle wasting will be covered.

New Transplant Therapy, Shift in Drug Discovery

A pathway is a sequence of reactions converting one molecule into another. Ubiquitin, which is a small protein, is used often to mark larger proteins within a cell for breakdown. This pathway plays fundamental roles in human health and disease; many human pathologies have been linked to changes in ubiquitin pathway enzymes. Attracting experts in this growing field, the three-day conference is unique in its focus on drug discovery within the ubiquitin pathway.

Rejection hurts; but for the recipient of organ donation, rejection can be fatal. New combination therapies for treating antibody-mediated rejection (AMR) in transplant patients are possible, thanks in part to manipulation of the ubiquitin pathway.

When a transplant recipient’s body rejects donor tissue, the recipient’s plasma cells, which typically fight off infection, are in fact the aggressors in the attack. Dr. Woodle suggests stalling the proteasome (or “cellular waste-bin”) via the ubiquitin pathway (or “cellular tagging and shipping information hub”) thereby depleting plasma cells and treating rejection. Dr. Woodle will present his latest findings during the final conference session.

Via EPR Network
More Biotech press releases